Universität zu Köln

Steven, Philipp, Augustin, Albert J., Geerling, Gerd, Kaercher, Thomas, Kretz, Florian, Kunert, Kathleen, Menzel-Severing, Johannes, Schrage, Norbert, Schrems, Wolfgang, Kroesser, Sonja, Beckert, Michael and Messmer, Elisabeth M. (2017). Semifluorinated Alkane Eye Drops for Treatment of Dry Eye Disease Due to Meibomian Gland Disease. J. Ocular Pharmacol. Ther., 33 (9). S. 678 - 686. NEW ROCHELLE: MARY ANN LIEBERT, INC. ISSN 1557-7732

Full text not available from this repository.

Abstract

Purpose: Meibomian gland disease is generally accepted as the leading cause for evaporative dry eye disease (DED). In a previous study, perfluorohexyloctane, a semifluorinated alkane, has been demonstrated to significantly increase tear film breakup time and to reduce corneal fluorescein staining in patients with evaporative DED, thereby vastly reducing dry eye-related symptoms. This study was set up to evaluate perfluorohexyloctane in a larger population of patients with Meibomian gland dysfunction. Methods: Seventy-two patients with Meibomian gland disease and associated dry eye received 1 drop of perfluorohexyloctane 4 times daily during an observational, prospective, multicenter, 6-8-week study. Clinical assessment included best-corrected visual acuity, intraocular pressure, Schirmer test I, tear film breakup time, anterior and posterior blepharitis assessment, number of expressible Meibomian glands, meibum quality and quantity, ocular surface fluorescein staining, lid margin and symptom assessment, and Ocular Surface Disease Index (OSDI (c)). Results: From the 72 patients recruited, 61 completed the trial per protocol. Nine patients did not apply the medication as recommended and 2 patients were lost to follow-up. Tear film breakup time, corneal and conjunctival fluorescein staining, number of expressible Meibomian glands, and severity of anterior and posterior blepharitis significantly improved after 6-8 weeks of perfluorohexyloctane application. In addition, symptoms improved as demonstrated by a significant decrease of OSDI-values from 37 (13) to 26 (+/- 16). Conclusions: In concordance with previous findings, 6-8 weeks of topical application of perfluorohexyloctane significantly improves clinical signs of Meibomian gland disease and associated mild to moderate DED.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Steven, Philipp UNSPECIFIED UNSPECIFIED UNSPECIFIED Augustin, Albert J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Geerling, Gerd UNSPECIFIED UNSPECIFIED UNSPECIFIED Kaercher, Thomas UNSPECIFIED UNSPECIFIED UNSPECIFIED Kretz, Florian UNSPECIFIED UNSPECIFIED UNSPECIFIED Kunert, Kathleen UNSPECIFIED UNSPECIFIED UNSPECIFIED Menzel-Severing, Johannes UNSPECIFIED UNSPECIFIED UNSPECIFIED Schrage, Norbert UNSPECIFIED UNSPECIFIED UNSPECIFIED Schrems, Wolfgang UNSPECIFIED UNSPECIFIED UNSPECIFIED Kroesser, Sonja UNSPECIFIED UNSPECIFIED UNSPECIFIED Beckert, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED Messmer, Elisabeth M. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-212908
DOI:	10.1089/jop.2017.0042
Journal or Publication Title:	J. Ocular Pharmacol. Ther.
Volume:	33
Number:	9
Page Range:	S. 678 - 686
Date:	2017
Publisher:	MARY ANN LIEBERT, INC
Place of Publication:	NEW ROCHELLE
ISSN:	1557-7732
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language TEAR FILM LIPIDS; INTERNATIONAL WORKSHOP; DYSFUNCTION REPORT; FATTY-ACIDS; SUBCOMMITTEE; MULTICENTER; SYMPTOMS; EFFICACY; OMEGA-3; INDEX Multiple languages Ophthalmology; Pharmacology & Pharmacy Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/21290